Magnesiocard I.V.

Magnesium L-Aspartate Hydrochloride Trihydrate, the active ingredient in Magnesiocard I.V., is a magnesium supplement presented as an intravenous solution for intravenous use. It is employed to correct magnesium deficiency and hypomagnesemia, and to provide electrolyte replacement in patients requiring rapid restoration of magnesium levels under clinical supervision in acute care settings.

GNH USA supplies Magnesiocard I.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with robust quality assurance and regulatory compliance.

Magnesiocard I.V. is used in the management of electrolyte disorders, specifically magnesium deficiency.

Magnesium deficiency: restores normal magnesium levels to support cellular function. Hypomagnesemia: rapidly corrects low serum magnesium in acute settings. Electrolyte replacement therapy: supplies magnesium as part of comprehensive electrolyte repletion protocols.

Adverse reactions to Magnesiocard I.V. are generally related to the intravenous administration of magnesium.

Common Side Effects: - Injection site pain - Flushing - Nausea -